Круглосуточно
+7 (965) 177 17 74

бесплатно по России

цаталодж 142241

При переходе к биологической терапии необходимо рассмотреть возможность подкожного введения, чтобы ограничить контакт пациента с медицинским учреждением. Выборочный переход от внутривенных инфузий инфликсимаба к препаратам анти-TNF с подкожным введением не рекомендуется, поскольку это может увеличить риск рецидива. Если пациент находится в контакте с человеком COVID-19, необходимо рассмотреть возможность отказа от терапии анти-TNF в течение 2 недель. Если у пациента положительный результат теста на SARS-CoV-2 и/или у него развивается COVID-19, необходимо рассмотреть возможность отказа от биопрепаратов до тех пор пока пациент не избавится от инфекции.

“For the second month, we see an increase in the number of coronavirus diseases. Over the past week, 24,000 new cases were recorded, the week before that there were 16,000, that is, there is a gradual increase. Our experts, together with WHO experts, predict that this year the peak incidence will be at the beginning October... In previous years, it was the end of October - the beginning of November. We are preparing for this in order to provide proper medical care," the minister said.

Skin lesions in coronavirus infection caused by the SARS-CoV-2 virus are divided into seven categories. The first category includes skin angiitis caused directly by COVID-19 infection, against which the walls of small vessels of the dermis are damaged by immune complexes circulating in the blood. Angiitis is localized on the skin of the upper and lower extremities. They look like frostbite, painful, itchy. Such manifestations usually occur in young patients with a mild course of the disease, appear in the late stages and last about 12 days. The second category includes papular-vesicular rashes, which are characterized by acute clinical manifestations in the form of chickenpox, more similar to prickly heat, occurring against a background of high fever and increased sweating.

If a patient tests positive for SARS-CoV-2 and/or develops COVID-19, discontinuation of biologics should be considered until the patient clears the infection. JAK inhibitors (tofacitinib and others) selectively affect the intracellular JAK/STAT signaling system, which mediates the action of many cytokines involved in the pathogenesis of ulcerative colitis. Unlike genetically engineered biological drugs, inhibition

Быстрая запись на прием

Ваше имя:* Телефон:* Выберите специализацию:* Выберите врача:

Дополнительная информация: